Filing Flows › bioAffinity Technologies (BIAF) › Q1 2026
bioAffinity Technologies (BIAF) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 11, 2026
bioAffinity Technologies (BIAF) reported revenue of $1.4M for the first quarter 2026 (Q1 2026), -27% from a year earlier and -15% from the quarter before. Operating margin was -267.6%, net loss $3.6M (268.6% of revenue).
bioAffinity Technologies, Q1 2026: revenue $1.4M (-27% year over year), operating margin -267.6%, net loss $3.6M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | -15% | -27% |
| Operating profit | −$3.6M | — | — |
| Net earnings | −$3.6M | — | — |
| Operating cash flow | −$3.2M | — | — |
What changed
Revenue was $1.4M in Q1 2026, down 27% year over year and down 15% from the previous quarter. Health Care, Patient Service was the largest line at 80% of revenue. Health Care, Patient Service lost $488K year over year (down 31%), 97% of the total change.
Operating costs exceeded revenue by $3.6M, an operating margin of -267.6%. Total costs grew 11% against a revenue fall of 27%. The fastest-growing cost line was SG&A (+32%). The quarter ended with a net loss of $3.6M, wider than the previous quarter's $3.1M loss.
Operating cash flow was −$3.2M. Non-cash charges added back $115K of depreciation and amortization and $14K of share-based compensation. Working capital and other items added $275K. Capital expenditures of $6K exceeded it, leaving free cash flow of −$3.2M.
Questions
What was bioAffinity Technologies' revenue in the first quarter 2026?
bioAffinity Technologies (BIAF) reported revenue of $1.4M for the first quarter 2026 (Q1 2026), -27% from a year earlier and -15% from the quarter before.
Was bioAffinity Technologies profitable in the first quarter 2026?
Operating loss was $3.6M (-267.6% of revenue) and net loss $3.6M.